Coronavirus disease 2019

From Encyclopedia Britannia
Jump to navigation Jump to search

Coronavirus disease 2019 (COVID-19)
Other names
  • Coronavirus
  • COVID
  • 2019-nCoV acute respiratory disease
  • Novel coronavirus pneumonia[1][2]
  • Severe pneumonia with novel pathogens[3]
Symptoms of coronavirus disease 2019 4.0.svg
Symptoms of COVID-19
Pronunciation
SpecialtyInfectious disease
SymptomsFever, cough, fatigue, shortness of breath, loss of smell; sometimes no symptoms at all[5][6][7]
ComplicationsPneumonia, viral sepsis, acute respiratory distress syndrome, kidney failure, cytokine release syndrome
Usual onset2–14 days (typically 5) from infection
CausesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Risk factorsTravel, viral exposure
Diagnostic methodrRT-PCR testing, CT scan
PreventionHand washing, face coverings, quarantine, social distancing[8]
TreatmentSymptomatic and supportive
Frequency4,687,320[9] confirmed cases
Deaths313,127 (6.7% of confirmed cases)[9]

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[10] It was first identified in December 2019 in Wuhan, China, and has since spread globally, resulting in an ongoing pandemic.[11][12] As of 17 May 2020, more than 4.68 million cases have been reported across 188 countries and territories, resulting in more than 313,000 deaths. More than 1.72 million people have recovered.[9]

Common symptoms include fever, cough, fatigue, shortness of breath, and loss of smell and taste.[6][7][13] While the majority of cases result in mild symptoms, some progress to an unusual form of acute respiratory distress syndrome (ARDS) likely precipitated by cytokine storm,[14] multi-organ failure, septic shock, and blood clots.[15][16][17] The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days.[6][18]

<section begin="Spread"/>The virus is primarily spread between people during close contact,[lower-alpha 1] most often via small droplets produced by coughing,[lower-alpha 2] sneezing, and talking.[7][19][21] The droplets usually fall to the ground or onto surfaces rather than travelling through air over long distances.[7] Less commonly, people may become infected by touching a contaminated surface and then touching their face.[7][19] It is most contagious during the first three days after the onset of symptoms, although spread is possible before symptoms appear, and from people who do not show symptoms.[7][19]<section end="Spread"/> The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab.[22] Chest CT imaging may also be helpful for diagnosis in individuals where there is a high suspicion of infection based on symptoms and risk factors; however, guidelines do not recommend using CT imaging for routine screening.[23][24]

Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), quarantine (especially for those with symptoms), covering coughs, and keeping unwashed hands away from the face.[8][25][26] In addition, the use of a face covering is recommended for those who suspect they have the virus and their caregivers.[27][28] Recommendations for face covering use by the general public vary, with some authorities recommending for them, some recommending against them, and others requiring their use.[28][29][30] There is limited evidence for or against the use of masks (medical or other) in healthy individuals in the wider community.[7]

According to the World Health Organization, there are no available vaccines nor specific antiviral treatments for COVID-19.[7] On 1 May 2020, the United States gave Emergency Use Authorization to the antiviral remdesivir for people hospitalized with severe COVID‑19.[31] Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.[32] The World Health Organization (WHO) declared the COVID‑19 outbreak a Public Health Emergency of International Concern (PHEIC)[33][34] on 30 January 2020 and a pandemic on 11 March 2020.[12] Local transmission of the disease has occurred in most countries across all six WHO regions.[35] File:En.Wikipedia-VideoWiki-Coronavirus disease 2019.webm

Signs and symptoms

Symptoms of COVID-19[5]
Symptom Range
Fever 83–99%
Cough 59–82%
Loss of appetite 40–84%
Fatigue 44–70%
Shortness of breath 31–40%
Coughing up sputum 28–33%
Muscle aches and pains 11–35%

Fever is the most common symptom, although some older people and those with other health problems experience fever later in the disease.[5][36]Template:Medrs In one study, 44% of people had fever when they presented to the hospital, while 89% went on to develop fever at some point during their hospitalization.[5][37] A lack of fever does not verify someone is disease free.

Other common symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, and muscle and joint pains.[1][5][6][38] Symptoms such as nausea, vomiting, and diarrhoea have been observed in varying percentages.[39][40][41] Less common symptoms include sneezing, runny nose, or sore throat.[42] Some cases in China initially presented with only chest tightness and palpitations.[43] A decreased sense of smell or disturbances in taste may occur.[44][45] Loss of smell was a presenting symptom in 30% of confirmed cases in South Korea.[13][46]

As is common with infections, there is a delay between the moment a person is first infected and the time he or she develops symptoms. This is called the incubation period. The average incubation period for COVID‑19 is five to six days but commonly ranges from two to 14 days,[47][7] and although uncommon cases may have a much longer incubation period, greater than 95% of people who develop symptoms will do so within 13 days of infection.[48]

A minority of cases do not develop noticeable symptoms at any point in time.[49][50] These asymptomatic carriers tend not to get tested, and their role in transmission is not yet fully known.[51][52] However, preliminary evidence suggests they may contribute to the spread of the disease.[53]

Complications

Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death.[11][15][54][55] Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots.[56] Approximately 20-30% of people who present with COVID‑19 have elevated liver enzymes reflecting liver injury.[57][58] Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome.[59]

Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, and die.[60]Template:Medrs

Cause

Transmission

<section begin="Transmission"/>

Cough/sneeze droplets visualised in dark background using Tyndall scattering
Respiratory droplets produced when a man sneezes, visualised using Tyndall scattering

File:COVID19 in numbers- R0, the case fatality rate and why we need to flatten the curve.webm

COVID‑19 is a new disease, and many of the details of its spread are still under investigation.[7][19][21] It spreads between people very efficiently and sustainably—easier than influenza but not as efficiently as measles[19]—mainly when in close contact (two metres or six feet), most often via small droplets produced during coughing sneezing or talking.[7][21] Contaminated droplets exhaled by infected people are then inhaled into the lungs, or settle on other people's faces to cause new infection.[19] The droplets are relatively heavy, usually fall to surfaces, and do not travel far through the air.[7][21] People can transmit the virus without showing symptoms, but according to the WHO and ECDC, it is unknown how often this happens.[7][19][21] One summary of available studies estimated the number of those infected who are asymptomatic to be 40%.[61]

People are most infectious when they show symptoms (even mild or non-specific symptoms), but may be infectious for up to two days before symptoms appear (pre-symptomatic transmission).[21] They remain infectious an estimated seven to twelve days in moderate cases and an average of two weeks in severe cases.[21]

When the contaminated droplets fall to floors or surfaces they can, though less commonly, remain infectious if people touch contaminated surfaces and then their eyes, nose or mouth with unwashed hands.[7] On surfaces the amount of active virus decreases over time until it can no longer cause infection,[21] and surfaces are thought not to be the main way the virus spreads.[19] It is unknown what amount of virus on surfaces is required to cause infection via this method, but it can be detected for up to four hours on copper, up to one day on cardboard, and up to three days on plastic (polypropylene) and stainless steel (AISI 304).[21][62][63] Surfaces are easily decontaminated with household disinfectants which kill the virus outside the human body or on the hands.[7] Disinfectants or bleach are not a treatment for COVID‑19, and cause health problems when not used properly, such as when used inside the human body.[64]

Sputum and saliva carry large amounts of virus.[7][19][21][65] Although COVID‑19 is not a sexually transmitted infection, kissing, intimate contact, and faecal-oral routes are suspected to transmit the virus.[66][67] Some medical procedures are aerosol-generating[68] and result in the virus being transmitted more easily than normal.[7][21]

Estimates of the number of people infected by one person with COVID-19 (the R0) have varied widely. The WHO's initial estimates of the R0 were 1.4-2.5 (average 1.95), however a more recent review found the basic R0 (without control measures) to be higher at 3.28 and the median R0 to be 2.79.[69] <section end="Transmission" />

Virology

Illustration of SARSr-CoV virion

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus, first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.[70] All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature.[71] Outside the human body, the virus is killed by household soap, which bursts its protective bubble.[23]

SARS-CoV-2 is closely related to the original SARS-CoV.[72] It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13).[42] In February 2020, Chinese researchers found that there is only one amino acid difference in the binding domain of the S protein between the coronaviruses from pangolins and those from humans; however, whole-genome comparison to date found that at most 92% of genetic material was shared between pangolin coronavirus and SARS-CoV-2, which is insufficient to prove pangolins to be the intermediate host.[73]

Pathophysiology

The lungs are the organs most affected by COVID‑19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell.[74] The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested decreasing ACE2 activity might be protective,[75][76] though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective.[77] As the alveolar disease progresses, respiratory failure might develop and death may follow.[76]

SARS-CoV-2 may also cause respiratory failure through affecting the brainstem as other coronaviruses have been found to invade the central nervous system (CNS). While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain.[78][79]

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium[80] as well as endothelial cells and enterocytes of the small intestine.[81]

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system.[82] An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,[40] and is more frequent in severe disease.[83] Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.[82] ACE2 receptors are highly expressed in the heart and are involved in heart function.[82][84] A high incidence of thrombosis (31%) and venous thromboembolism (25%) have been found in ICU patients with COVID‑19 infections and may be related to poor prognosis.[85][86] Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.[87]

Another common cause of death is complications related to the kidneys.[87] Early reports show that up to 30% of hospitalized patients in both China and New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.[88]

Autopsies of people who died of COVID‑19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.[89]

Immunopathology

Although SARS-COV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID‑19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.[40]

Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.[90]

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID‑19 patients.[91] Lymphocytic infiltrates have also been reported at autopsy.[89]

Diagnosis

Demonstration of a nasopharyngeal swab for COVID-19 testing
CDC rRT-PCR test kit for COVID-19[92]

The WHO has published several testing protocols for the disease.[93] The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR).[94] The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.[22][95] Results are generally available within a few hours to two days.[96][97] Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value.[98] Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus.[11][99][100] As of 4 April 2020, antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used.[101][102][103] The Chinese experience with testing has shown the accuracy is only 60 to 70%.[104] The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.[105]

Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count.[106]

A study asked hospitalised COVID‑19 patients to cough into a sterile container, thus producing a saliva sample, and detected the virus in eleven of twelve patients using RT-PCR. This technique has the potential of being quicker than a swab and involving less risk to health care workers (collection at home or in the car).[65]

Along with laboratory testing, chest CT scans may be helpful to diagnose COVID‑19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.[23][24] Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection.[23] Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.[23][107]

In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID‑19 without lab-confirmed SARS-CoV-2 infection.[108]

Typical CT imaging findings
CT imaging of rapid progression stage

Pathology

Few data are available about microscopic lesions and the pathophysiology of COVID‑19.[109][110] The main pathological findings at autopsy are:

Prevention

Progressively stronger mitigation efforts to reduce the number of active cases at any given time—"flattening the curve"—allows healthcare services to better manage the same volume of patients.[114][115][116] Likewise, progressively greater increases in healthcare capacity—called raising the line—such as by increasing bed count, personnel, and equipment, helps to meet increased demand.[117]
Mitigation attempts that are inadequate in strictness or duration—such as premature relaxation of distancing rules or stay-at-home orders—can allow a resurgence after the initial surge and mitigation.[115][118]

Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, keeping distance from others, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.[119][120][121] The U.S. Centers for Disease Control and Prevention (CDC) recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.[119] Proper hand hygiene after any cough or sneeze is encouraged.[119] The CDC has recommended cloth face coverings in public settings where other social distancing measures are difficult to maintain, in part to limit transmission by asymptomatic individuals.[122] The U.S. National Institutes of Health guidelines do not recommend any medication for prevention of COVID‑19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial.[123]

Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings.[124] Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.[125] There is no medication known to be effective at preventing COVID‑19.[126] After the implementation of social distancing and stay-at-home orders, many regions have been able to sustain an effective transmission rate ("Rt") of less than one, meaning the disease is in remission in those areas.[127] In a simple model <math display="inline">\ln(R_t)\approx R_t-1</math> needs on average over time be kept at or below zero to avoid exponential growth.[citation needed]

As a COVID-19 vaccine is not expected until 2021 at the earliest,[128] a key part of managing COVID‑19 is trying to decrease and delay the epidemic peak, known as "flattening the curve".[115] This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.[115][118]

According to the WHO, the use of masks is recommended only if a person is coughing or sneezing or when one is taking care of someone with a suspected infection.[129] For the European Centre for Disease Prevention and Control (ECDC) face masks "... could be considered especially when visiting busy closed spaces ..." but "... only as a complementary measure ..."[130] Several countries have recommended that healthy individuals wear face masks or cloth face coverings (like scarves or bandanas) at least in certain public settings, including China,[131] Hong Kong,[132] Spain,[133] Italy (Lombardy region),[134] Russia,[135] and the United States.[122]

Those diagnosed with COVID‑19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.[27][136] The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing. It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.[119]

For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.[137]

Management

People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.[138][139][140] The CDC recommends those who suspect they carry the virus wear a simple face mask.[27] Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.[37][141] Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.[142] Supportive treatments may be useful in those with mild symptoms at the early stage of infection.[143]

The WHO, the Chinese National Health Commission, and the United States' National Institutes of Health have published recommendations for taking care of people who are hospitalised with COVID‑19.[123][144][145] Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.[146][147]

Medications

Per the World Health Organization, as of April 2020, there is no specific treatment for COVID‑19.[7] On May 1, 2020, the United States gave Emergency Use Authorization (not full approval) for remdesivir in people hospitalized with severe COVID‑19 after a study suggested it reduced the duration of recovery.[31][148] Researchers continue working on more effective treatments and many vaccine candidates are in development or testing phases.[citation needed]

For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.[149][150][151] The WHO and NIH do not oppose the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen for symptoms,[123][152] and the FDA says currently there is no evidence that NSAIDs worsen COVID‑19 symptoms.[153]

While theoretical concerns have been raised about ACE inhibitors and angiotensin receptor blockers, as of 19 March 2020, these are not sufficient to justify stopping these medications.[123][154][155][156] One study from April 22 found that people with COVID‑19 and hypertension had lower all-cause mortality when on these medications.[157]

Steroids, such as methylprednisolone, are not recommended unless the disease is complicated by acute respiratory distress syndrome.[158][159]

The Australasian Society of Clinical Immunology and Allergy recommend that tocilizumab be considered an off-label treatment option for those with COVID‑19-related acute respiratory distress syndrome. It recommends this because of its known benefit in cytokine storm caused by a specific cancer treatment, and that cytokine storm may be a significant contributor to mortality in severe COVID‑19.[14]

Medications to prevent blood clotting have been suggested for treatment,[85] and anticoagulant therapy with low molecular weight heparin appears to be associated with better outcomes in severe COVID‐19 showing signs of coagulopathy (elevated D-dimer).[160]

Protective equipment

The U.S. Centers for Disease Control and Prevention (CDC) recommends four steps to putting on personal protective equipment (PPE).[161]

Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.[162] For healthcare professionals caring for people with COVID‑19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions, and airborne precautions.[163]

The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic. The recommended gear is a PPE gown, respirator or facemask, eye protection, and medical gloves.[164][165]

When available, respirators (instead of facemasks) are preferred.[166] N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA). They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.[167] When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.[168]

Mechanical ventilation

Most cases of COVID‑19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.[169][170] The type of respiratory support for individuals with COVID‑19 related respiratory failure is being actively studied for people in the hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.[171] Whether either of these two leads to the same benefit for people who are critically ill is not known.[172] Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.[169]

Severe cases are most common in older adults (those older than 60 years,[169] and especially those older than 80 years).[49] Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID‑19 cases severe enough to require hospitalisation.[173] This limited capacity is a significant driver behind calls to flatten the curve.[173] One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.[37] In China, approximately 30% of people in hospital with COVID‑19 are eventually admitted to ICU.[5]

Acute respiratory distress syndrome

Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID‑19 and oxygenation becomes increasingly difficult.[174] Ventilators capable of pressure control modes and high PEEP[175] are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.[176] High PEEP may not be available on older ventilators.[citation needed]

There is high mortality in ventilated patients in COVID-19, thought to be due to cytokine storm. Blockade of the IL-6 system is recommended by Australasian Society for Immunology and Allergy to be considered early in severe disease, and is included for consideration in a number of national guidelines. [14]

Options for ARDS[174]
Therapy Recommendations
High-flow nasal oxygen For SpO2 <93%. May prevent the need for intubation and ventilation
Tidal volume 6mL per kg and can be reduced to 4mL/kg
Plateau airway pressure Keep below 30 cmH2O if possible (high respiratory rate (35 per minute) may be required)
Positive end-expiratory pressure Moderate to high levels
Prone positioning For worsening oxygenation
Fluid management Goal is a negative balance of 0.5–1.0L per day
Antibiotics For secondary bacterial infections
Glucocorticoids Not recommended

Experimental treatment

Research into potential treatments started in January 2020,[177] and several antiviral drugs are in clinical trials.[178][179] Remdesivir appears to be the most promising.[126] Although new medications may take until 2021 to develop,[180] several of the medications being tested are already approved for other uses or are already in advanced testing.[181] Antiviral medication may be tried in people with severe disease.[138] The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.[182]

The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened. It has not undergone the clinical studies needed to show it is safe and effective for the disease.[183][184][185]

Information technology

In February 2020, China launched a mobile app to deal with the disease outbreak.[186] Users are asked to enter their name and ID number. The app can detect 'close contact' using surveillance data and therefore a potential risk of infection. Every user can also check the status of three other users. If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.[187]

Big data analytics on cellphone data, facial recognition technology, mobile phone tracking, and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan, and Singapore.[188][189] In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus. According to the Israeli government, the measure was taken to enforce quarantine and protect those who may come into contact with infected citizens. The Association for Civil Rights in Israel, hover, said that the move was "a dangerous precedent and a slippery slope".[190] Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, to research and prevent the spread of the virus.[191] Russia deployed facial recognition technology to detect quarantine breakers.[192] Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".[193] German government conducted a 48 hours weekend hackathon with more than 42.000 participants.[194][195] Three million people in the UK used an app developed by King's College London and Zoe to track people with COVID‑19 symptoms.[196][197] Also, the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.[198]

Psychological support

Individuals may experience distress from quarantine, travel restrictions, side effects of treatment, or fear of the infection itself. To address these concerns, the National Health Commission of China published a national guideline for psychological crisis intervention on 27 January 2020.[199][200]

The Lancet published a 14-page call for action focusing on the UK and stated conditions were such that a range of mental health issues was likely to become more common. BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress, and an economic downturn are a perfect storm to harm people's mental health and wellbeing."[201][202]

Prognosis

The severity of diagnosed cases in China
The severity of diagnosed COVID-19 cases in China[203]
Case fatality rates for COVID-19 by age by country.
Case fatality rates by age group:
  China, as of 11 February 2020[204]
  South Korea, as of 13 May 2020[205]
  Spain, as of 12 May 2020[206]
  Italy, as of 7 May 2020[207]
Case fatality rate depending on other health problems
Case fatality rate in China depending on other health problems. Data through 11 February 2020.[204]
Case fatality rate by country and number of cases
The number of deaths vs total cases by country and approximate case fatality rate[208]

The severity of COVID‑19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks.[42]

Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years.[21] They are likely to have milder symptoms and a lower chance of severe disease than adults; in those younger than 50 years the risk of death is less than 0.5%, while in those older than 70 it is more than 8%.[209][210][211] Pregnant women may be at higher risk for severe infection with COVID‑19 based on data from other similar viruses, like Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), but data for COVID‑19 is lacking.[212][213] In China, children acquired infections mainly through close contact with their parents or other family members who lived in Wuhan or had traveled there.[209]

Some studies have found that the neutrophil to lymphocyte ratio (NLR) may be helpful in early screening for severe illness.[214]

Most of those who die of COVID‑19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease.[215] The Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available for review, 97.2% of sampled patients had at least one comorbidity with the average patient having 2.7 diseases.[216] According to the same report, the median time between the onset of symptoms and death was ten days, with five being spent hospitalised. However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.[216] In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.[217] In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.[218] Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs. Viral cytopathic changes were observed in the pneumocytes. The lung picture resembled acute respiratory distress syndrome (ARDS).[42] In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.[43] According to March data from the United States, 89% of those hospitalised had preexisting conditions.[219]

The availability of medical resources and the socioeconomics of a region may also affect mortality.[220] Estimates of the mortality from the condition vary because of those regional differences,[221] but also because of methodological difficulties. The under-counting of mild cases can cause the mortality rate to be overestimated.[222] However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.[223][224] Smokers were 1.4 times more likely to have severe symptoms of COVID‑19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.[225]

Concerns have been raised about long-term sequelae of the disease. The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.[226] This may also lead to post-intensive care syndrome following recovery.[227]

Case fatality rates (%) by age and country
Age 0–9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80-89 90+
Argentina as of 7 May[228] 0.0 0.0 0.1 0.4 1.3 3.6 12.9 18.8 28.4
Australia as of 13 May[229] 0.0 0.0 0.0 0.0 0.1 0.2 1.0 4.2 18.1 39.6
Canada as of 12 May[230] 0.0 0.1 0.7 7.2 24.8
Chile as of 11 May[231] 0.0 0.3 0.5 2.5 7.4 16.7
China as of 11 February[204] 0.0 0.2 0.2 0.2 0.4 1.3 3.6 8.0 14.8
Denmark as of 13 May[232] 0.2 4.1 16.3 27.0 48.1
Finland as of 8 May[233] 0.0 0.0 0.0 <0.5 <0.5 0.5 2.6 13.4 32.9
Germany as of 9 May[234] 0.0 0.0 0.1 1.7 18.2 28.5
Israel as of 3 May[235] 0.0 0.0 0.0 0.9 0.9 3.1 9.7 22.9 30.8 31.3
Italy as of 7 May[207] 0.2 0.0 0.1 0.3 0.9 2.6 10.2 24.8 30.0 26.1
Japan as of 7 May[236] 0.0 0.0 0.0 0.1 0.3 0.6 2.5 6.8 14.8
Netherlands as of 8 May[237] 0.0 0.2 0.1 0.2 0.5 1.6 8.0 25.2 32.2 32.7
Norway as of 8 May[238] 0.0 0.0 0.0 0.0 0.2 0.4 1.7 8.5 21.3 50.4
Portugal as of 13 May[239] 0.0 0.0 0.0 0.0 0.3 0.8 3.3 9.7 18.0
South Korea as of 13 May[205] 0.0 0.0 0.0 0.2 0.2 0.8 2.7 10.8 25.5
Spain as of 12 May[206] 0.2 0.3 0.2 0.3 0.6 1.4 4.9 14.1 20.8 22.0
Sweden as of 13 May[240] 0.0 0.0 0.3 0.4 0.9 2.2 7.1 23.0 34.3 38.2
Switzerland as of 13 May[241] 0.0 0.0 0.0 0.1 0.1 0.6 3.1 11.2 26.9
United States
     Connecticut as of 11 May[242] 0.3 0.1 0.1 0.4 0.8 2.1 7.4 19.7 35.7
     Idaho as of 9 May[243] 0.0 0.0 0.0 0.0 0.0 0.5 3.2 8.2 28.9
     Kentucky as of 5 May[244] 0.0 0.0 0.0 0.2 0.6 2.3 6.8 13.3 27.9
     Maryland as of 9 May[245] 0.0 0.0 0.3 0.3 0.7 1.8 5.6 13.3 26.5
     Massachusetts as of 12 May[246] 0.0 0.0 0.1 0.1 0.4 1.4 4.8 15.7 26.6
     Mississippi as of 7 May[247] 0.1 0.6 0.9 1.8 7.3 15.3 17.8 23.8
     N. Hampshire as of 5 May[248] 0.0 0.0 0.3 0.0 1.1 0.0 2.1 7.7 18.4
     Oregon as of 12 May[249] 0.0 0.0 0.0 0.0 0.5 0.9 4.9 12.5 27.1
     Texas as of 8 May[250] 0.0 0.5 0.5 0.4 0.8 2.0 13.5 25.8 30.0
     Virginia as of 12 May[251] 0.0 0.0 0.1 0.1 0.4 1.1 4.6 12.5 24.3
     Washington as of 10 May[252] 0.0 0.2 1.4 9.5 30.6
Estimate of infection fatality rates and probability of severe disease course (%) by age based on cases from China[253]
0–9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80+
Severe disease 0.0
(0.0–0.0)
0.04
(0.02–0.08)
1.0
(0.62–2.1)
3.4
(2.0–7.0)
4.3
(2.5–8.7)
8.2
(4.9–17)
11
(7.0–24)
17
(9.9–34)
18
(11–38)
Death 0.0016
(0.00016–0.025)
0.0070
(0.0015–0.050)
0.031
(0.014–0.092)
0.084
(0.041–0.19)
0.16
(0.076–0.32)
0.60
(0.34–1.3)
1.9
(1.1–3.9)
4.3
(2.5–8.4)
7.8
(3.8–13)
Total infection fatality rate is estimated to be 0.66% (0.39–1.3). Infection fatality rate is fatality per all infected individuals, regardless of whether they were diagnosed or had any symptoms. Numbers in parentheses are 95% credible intervals for the estimates.

Immunity

It is unknown (as of April 2020) if past infection provides effective and long-term immunity in people who recover from the disease.[254][255] Some of the infected have been reported to develop protective antibodies, so acquired immunity is presumed likely, based on the behaviour of other coronaviruses.[256] Cases in which recovery from COVID‑19 was followed by positive tests for coronavirus at a later date have been reported.[257][258][259][260] However, these cases are believed to be lingering infection rather than reinfection,[260] or false positives due to remaining RNA fragments.[261] Some other coronaviruses circulating in people are capable of reinfection after roughly a year.[262][263]

History

The virus is thought to be natural and has an animal origin,[71] through spillover infection.[264] The actual origin is unknown, but the first known cases of infection happened in China. By December 2019, the spread of infection was almost entirely driven by human-to-human transmission.[204][265] A study of the first 41 cases of confirmed COVID‑19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.[266][267][268] Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.[269] Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020.[270][271]

Epidemiology

Several measures are commonly used to quantify mortality.[272] These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.[273]

The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.7% (313,127/4,687,320) as of 17 May 2020.[9] The number varies by region.[274]

Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease. These statistics are not time-bound and follow a specific population from infection through case resolution. Many academics have attempted to calculate these numbers for specific populations.[275]

Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing.[276][277] In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID‑19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.[276]

Total confirmed cases over time
Total deaths over time
Total confirmed cases of COVID‑19 per million people[278]
Total confirmed deaths due to COVID‑19 per million people[279]

Infection fatality rate

Our World in Data states that as of March 25, 2020, the infection fatality rate (IFR) cannot be accurately calculated.[280] In February, one research group estimated the IFR at 0.94%, with a confidence interval between 0.37 percent to 2.9 percent.[281] The University of Oxford Centre for Evidence-Based Medicine (CEBM) estimated a global CFR of 0.72 percent and IFR of 0.1 percent to 0.36 percent.[282] According to CEBM, random antibody testing in Germany suggested an IFR of 0.37% (0.12% to 0.87%) there, but there have been concerns about false positives.[282][283][284][285][286] Firm lower limits of infection fatality rates have been established in a number of locations. As of May 7, in New York City, with a population of 8.4 million, 14,162 have died from COVID-19 (0.17% of the population).[287] In Bergamo province, 0.57% of the population has died.[288][289][290] To get a better view on the number of people infected initial antibody testing have been carried out, but there are no valid scientific reports based on any of them as of yet.[291][292] On May 1 antibody testing in New York suggested an IFR of 0.86%.[293]

Sex differences

The impact of the pandemic and its mortality rate are different for men and women.[294] Mortality is higher in men in studies conducted in China and Italy.[1][295][296] The higher risk for men appears in their 50s, and begins to taper off only at 90.[296] In China, the death rate was 2.8 percent for men and 1.7 percent for women.[296] The exact reasons for this sex-difference are not known, but genetic and behavioural factors could be a reason.[294] Sex-based immunological differences, a lower prevalence of smoking in women, and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.[296] In Europe, of those infected with COVID‑19, 57% were men; of those infected with COVID‑19 who also died, 72% were men.[297] As of April 2020, the U.S. government is not tracking sex-related data of COVID‑19 infections.[298] Research has shown that viral illnesses like Ebola, HIV, influenza, and SARS affect men and women differently.[298] A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.[299] School closures, lockdowns, and reduced access to healthcare following the COVID-19 pandemic may differentially affect the genders and possibly exaggerate existing gender disparity.[294][300]

Ethnic differences

In the U.S., a greater proportion of deaths due to COVID-19 have occurred among African Americans.[301] Structural factors that prevent African Americans from practicing social distancing include their concentration in crowded substandard housing and "essential" occupations such as public transit employees and health-care workers. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death.[302] Similar issues affect Native American and Latino communities.[301] According to a U.S health policy non-profit 34% of American Indian and Alaska Native People (AIAN) nonelderly adults are at risk of serious illness compared to 21% of White nonelderly adults.[1] The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water.[303] Leaders have called for efforts to research and address the disparities.[304]

Existing respiratory problems

When someone with existing respiratory problems is infected with COVID-19, they are at greater risk for severe symptoms.[305] COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.[306]

Society and culture

Name

During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus",[307][308][309] with the disease sometimes called "Wuhan pneumonia".[310][311] In the past, many diseases have been named after geographical locations, such as the Spanish flu,[312] Middle East Respiratory Syndrome, and Zika virus.[313]

In January 2020, the World Health Organisation recommended 2019-nCov[314] and 2019-nCoV acute respiratory disease[315] as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species or groups of people in disease and virus names to prevent social stigma.[316][317][318]

The official names COVID‑19 and SARS-CoV-2 were issued by the WHO on 11 February 2020.[319] WHO chief Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019).[320] The WHO additionally uses "the COVID‑19 virus" and "the virus responsible for COVID‑19" in public communications.[319] Both the disease and virus are commonly referred to as "coronavirus" in the media and public discourse.

Misinformation

After the initial outbreak of COVID‑19, conspiracy theorists spread misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease, which rapidly spread online.[321][322][323]

Decreased emergency room use

In Austria, 39% fewer persons sought help for cardiac symptoms in the month of March. A study estimated that there were 110 incidents of preventable cardiac death as compared to 86 confirmed deaths from Coronavirus as of March 29.[324]

A preliminary study in the U.S. found 38% under-utilization of cardiac care units as compared to normal.[325] The head of cardiology at the University of Arizona has stated, "My worry is some of these people are dying at home because they're too scared to go to the hospital."[326] There is also concern that persons with symptoms of stroke and appendicitis are delaying seeking help.[326][327]

Other animals

Humans appear to be capable of spreading the virus to some other animals. A domestic cat in Liège, Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive.[328] Tigers and Lions at the Bronx Zoo in New York, United States, tested positive for the virus and showed symptoms of COVID‑19, including a dry cough and loss of appetite.[329] Minks at two farms in the Netherlands also tested positive for COVID-19.[330]

A study on domesticated animals inoculated with the virus found that cats and ferrets appear to be "highly susceptible" to the disease, while dogs appear to be less susceptible, with lower levels of viral replication. The study failed to find evidence of viral replication in pigs, ducks, and chickens.[331]

Research

No medication or vaccine is approved to treat the disease.[181] International research on vaccines and medicines in COVID‑19 is underway by government organisations, academic groups, and industry researchers.[332][333] In March, the World Health Organisation initiated the "SOLIDARITY Trial" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy.[334]

There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand. To minimise the impact of misinformation, medical professionals and the public are advised to expect rapid changes to available information, and to be attentive to retractions and other updates.[335]

Vaccine

There is no available vaccine, but various agencies are actively developing vaccine candidates. Previous work on SARS-CoV is being used because both SARS-CoV and SARS-CoV-2 use the ACE2 receptor to enter human cells.[336] Three vaccination strategies are being investigated. First, researchers aim to build a whole virus vaccine. The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID‑19. A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus. In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor. A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination). Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.[337]

On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle, Washington, United States. The vaccine contains a harmless genetic code copied from the virus that causes the disease.[338]

Antibody-dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.[339]

Medications

At least 29 phase II–IV efficacy trials in COVID‑19 were concluded in March 2020, or scheduled to provide results in April from hospitals in China.[340][341] There are more than 300 active clinical trials underway as of April 2020.[126] Seven trials were evaluating already approved treatments, including four studies on hydroxychloroquine or chloroquine.[341] Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.[340][341] Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.[341]

The COVID‑19 Clinical Research Coalition has goals to 1) facilitate rapid reviews of clinical trial proposals by ethics committees and national regulatory agencies, 2) fast-track approvals for the candidate therapeutic compounds, 3) ensure standardised and rapid analysis of emerging efficacy and safety data and 4) facilitate sharing of clinical trial outcomes before publication.[342][343]

Several existing medications are being evaluated for the treatment of COVID‑19,[181] including remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta.[334][344] There is tentative evidence for efficacy by remdesivir, as of March 2020.[345][346] Clinical improvement was observed in patients treated with compassionate-use remdesivir.[347] Remdesivir inhibits SARS-CoV-2 in vitro.[348] Phase III clinical trials are underway in the U.S., China, and Italy.[181][340][349]

In 2020, a trial found that lopinavir/ritonavir was ineffective in the treatment of severe illness.[350] Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.[348]

There are mixed results as of 3 April 2020 as to the effectiveness of hydroxychloroquine as a treatment for COVID‑19, with some studies showing little or no improvement.[351][352] The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.[126]

Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID‑19 treatment.[126]

Anti-cytokine storm

Cytokine release syndrome (CRS) can be a complication in the later stages of severe COVID‑19. There is preliminary evidence that hydroxychloroquine may have anti-cytokine storm properties.[353]

Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.[354][355] It is undergoing a phase 2 non-randomised trial at the national level in Italy after showing positive results in people with severe disease.[356][357] Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.[358][359][360] The interleukin-6 receptor antagonist was approved by the FDA to undergo a phase III clinical trial assessing the medication's impact on COVID‑19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.[361] To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no impact on the incidence of CRS.[362]

Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID‑19.[363]

The Feinstein Institute of Northwell Health announced in March a study on "a human antibody that may prevent the activity" of IL-6.[364]

Passive antibodies

Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID‑19 to people who need them is being investigated as a non-vaccine method of passive immunisation.[365] This strategy was tried for SARS with inconclusive results.[365] Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.[365] Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.[365] Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.[366]

See also

Notes

  1. Close contact is defined as one metre (~3.3 feet) by the WHO[7] and ~1.8 meters (six feet) by the CDC.[19]
  2. An uncovered cough can travel up to 8.2 metres (27 feet).[20]

References

  1. 1.0 1.1 1.2 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (February 2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. PMC 7135076. PMID 32007143.
  2. Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. (March 2020). "Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery". Clinical Infectious Diseases. doi:10.1093/cid/ciaa271. PMC 7184369. PMID 32227091.
  3. "Special Act for Prevention, Relief and Revitalization Measures for Severe Pneumonia with Novel Pathogens - Article Content - Laws & Regulations Database of The Republic of China". law.moj.gov.tw. Retrieved 10 May 2020.
  4. "Covid-19, n." Oxford English Dictionary. Retrieved 15 April 2020.
  5. 5.0 5.1 5.2 5.3 5.4 5.5 "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
  6. 6.0 6.1 6.2 6.3 "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 20 March 2020. Archived from the original on 30 January 2020.
  7. 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 "Q&A on coronaviruses (COVID-19)". World Health Organization (WHO). 17 April 2020. Archived from the original on 14 May 2020. Retrieved 14 May 2020.
  8. 8.0 8.1 Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. (April 2020). "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review". The Cochrane Database of Systematic Reviews. 4: CD013574. doi:10.1002/14651858.CD013574. PMC 7141753. PMID 32267544.
  9. 9.0 9.1 9.2 9.3 "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 17 May 2020.
  10. "Coronavirus disease 2019 (COVID-19)—Symptoms and causes". Mayo Clinic. Retrieved 14 April 2020.
  11. 11.0 11.1 11.2 Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264–266. doi:10.1016/j.ijid.2020.01.009. PMC 7128332. PMID 31953166.
  12. 12.0 12.1 "WHO Director-General's opening remarks at the media briefing on COVID-19". World Health Organization (WHO) (Press release). 11 March 2020. Archived from the original on 11 March 2020. Retrieved 12 March 2020.
  13. 13.0 13.1 Hopkins C. "Loss of sense of smell as marker of COVID-19 infection". Ear, Nose and Throat surgery body of United Kingdom. Retrieved 28 March 2020.
  14. 14.0 14.1 14.2 Grainger S. "ASCIA Position Statement: Specific Treatments for COVID-19". Australasian Society of Clinical Immunology and Allergy (ASCIA). Retrieved 2 May 2020.
  15. 15.0 15.1 Murthy S, Gomersall CD, Fowler RA (March 2020). "Care for Critically Ill Patients With COVID-19". JAMA. 323 (15): 1499. doi:10.1001/jama.2020.3633. PMID 32159735.
  16. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32150360. Retrieved 18 March 2020.
  17. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. (April 2020). "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2020.04.031. PMC 7164881. PMID 32311448.
  18. Velavan TP, Meyer CG (March 2020). "The COVID-19 epidemic". Tropical Medicine & International Health. 25 (3): 278–280. doi:10.1111/tmi.13383. PMC 7169770. PMID 32052514.
  19. 19.0 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 "How COVID-19 Spreads". Centers for Disease Control and Prevention (CDC). 2 April 2020. Archived from the original on 3 April 2020. Retrieved 3 April 2020.
  20. Bourouiba L (March 2020). "Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19". JAMA. doi:10.1001/jama.2020.4756. PMID 32215590.
  21. 21.00 21.01 21.02 21.03 21.04 21.05 21.06 21.07 21.08 21.09 21.10 21.11 "Q & A on COVID-19". European Centre for Disease Prevention and Control. Retrieved 30 April 2020.
  22. 22.0 22.1 "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 26 March 2020.
  23. 23.0 23.1 23.2 23.3 23.4 Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (March 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology: 1–7. doi:10.2214/AJR.20.23034. PMID 32174129.
  24. 24.0 24.1 "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020. Archived from the original on 28 March 2020.
  25. "Advice for public". World Health Organization (WHO). Archived from the original on 26 January 2020. Retrieved 25 February 2020.
  26. "Guidance on social distancing for everyone in the UK". GOV.UK. Archived from the original on 24 March 2020. Retrieved 25 March 2020.
  27. 27.0 27.1 27.2 Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
  28. 28.0 28.1 "When and how to use masks". World Health Organization (WHO). Archived from the original on 7 March 2020. Retrieved 24 April 2020.
  29. Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ (May 2020). "Rational use of face masks in the COVID-19 pandemic". The Lancet. Respiratory Medicine. 8 (5): 434–436. doi:10.1016/S2213-2600(20)30134-X. PMC 7118603. PMID 32203710.
  30. Tait R (30 March 2020). "Czechs get to work making masks after government decree". The Guardian. ISSN 0261-3077. Archived from the original on 30 March 2020. Retrieved 31 March 2020.
  31. 31.0 31.1 "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment". U.S. Food and Drug Administration (FDA) (Press release). 1 May 2020. Retrieved 1 May 2020.
  32. "How to Protect Yourself & Others". Centers for Disease Control and Prevention (CDC). 8 April 2020. Archived from the original on 26 February 2020. Retrieved 9 April 2020.
  33. "Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 11 February 2020.
  34. Mahtani S, Berger M, O'Grady S, Iati M (6 February 2020). "Hundreds of evacuees to be held on bases in California; Hong Kong and Taiwan restrict travel from mainland China". The Washington Post. Archived from the original on 7 February 2020. Retrieved 11 February 2020.
  35. "WHO Situation Report #87" (PDF). World Health Organization (WHO). 16 April 2020.
  36. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. (May 2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". The Lancet. Respiratory Medicine. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. PMC 7102538. PMID 32105632. ... 52 critically ill adult patients ... fever (98%) ... [of which] fever was not detected at the onset of illness in six (11·5%) ...
  37. 37.0 37.1 37.2 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (April 2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". The New England Journal of Medicine. Massachusetts Medical Society. 382 (18): 1708–1720. doi:10.1056/nejmoa2002032. PMC 7092819. PMID 32109013.
  38. Hessen MT (27 January 2020). "Novel Coronavirus Information Center: Expert guidance and commentary". Elsevier Connect. Archived from the original on 30 January 2020. Retrieved 31 January 2020.
  39. Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, et al. (26 February 2020). "Clinical Characteristics of SARS-CoV-2 Infected Pneumonia with Diarrhea". doi:10.2139/ssrn.3546120.
  40. 40.0 40.1 40.2 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (February 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264.
  41. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (March 2020). "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges". International Journal of Antimicrobial Agents. 55 (3): 105924. doi:10.1016/j.ijantimicag.2020.105924. PMC 7127800. PMID 32081636.
  42. 42.0 42.1 42.2 42.3 Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (PDF) (Report). World Health Organization (WHO). 16–24 February 2020. Archived (PDF) from the original on 29 February 2020. Retrieved 21 March 2020.
  43. 43.0 43.1 Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904.
  44. Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, Bauer C, Hautefort C, et al. (April 2020). "Smell and taste dysfunction in patients with COVID-19". The Lancet. Infectious Diseases. doi:10.1016/S1473-3099(20)30293-0. PMC 7159875. PMID 32304629.
  45. "Symptoms of Coronavirus". Centers for Disease Control and Prevention (CDC). 27 April 2020. Retrieved 28 April 2020.
  46. Iacobucci G (March 2020). "Sixty seconds on . . . anosmia". BMJ. 368: m1202. doi:10.1136/bmj.m1202. PMID 32209546.
  47. World Health Organization (19 February 2020). "Coronavirus disease 2019 (COVID-19): situation report, 29". World Health Organization (WHO). hdl:10665/331118.
  48. Nie, Xiuquan; Fan, Lieyang; Mu, Ge; Tan, Qiyou; Wang, Mengyi; Xie, Yujia; Cao, Limin; Zhou, Min; Zhang, Zhuang; Chen, Weihong (27 April 2020). "Epidemiological Characteristics and Incubation Period of 7015 Confirmed Cases With Coronavirus Disease 2019 Outside Hubei Province in China". The Journal of infectious diseases. Oxford University Press (OUP). doi:10.1093/infdis/jiaa211. ISSN 0022-1899. PMC 7197553. PMID 32339231.
  49. 49.0 49.1 Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M (16 March 2020). Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand (Report). Imperial College London. Table 1. doi:10.25561/77482. hdl:20.1000/100. Archived from the original on 21 March 2020. Retrieved 25 March 2020.
  50. Mizumoto K, Kagaya K, Zarebski A, Chowell G (March 2020). "Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020" (PDF). Euro Surveillance. 25 (10). doi:10.2807/1560-7917.ES.2020.25.10.2000180. PMC 7078829. PMID 32183930.
  51. "Clinical Questions about COVID-19: Questions and Answers". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 14 February 2020. Retrieved 31 March 2020.
  52. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. (March 2020). "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. doi:10.1016/j.jmii.2020.02.012. PMC 7128959. PMID 32173241.
  53. Furukawa NW, Brooks JT, Sobel J (2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerg Infect Dis. 26 (7). doi:10.3201/eid2607.201595. PMID 32364890.CS1 maint: multiple names: authors list (link)
  54. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32150360. Retrieved 18 March 2020.
  55. Heymann DL, Shindo N, et al. (WHO Scientific and Technical Advisory Group for Infectious Hazards) (February 2020). "COVID-19: what is next for public health?". Lancet. Elsevier BV. 395 (10224): 542–545. doi:10.1016/s0140-6736(20)30374-3. PMC 7138015. PMID 32061313.
  56. Long B, Brady WJ, Koyfman A, Gottlieb M (April 2020). "Cardiovascular complications in COVID-19". The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2020.04.048. PMC 7165109. PMID 32317203.
  57. Xu L, Liu J, Lu M, Yang D, Zheng X (May 2020). "Liver injury during highly pathogenic human coronavirus infections". Liver International. 40 (5): 998–1004. doi:10.1111/liv.14435. PMID 32170806.
  58. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. doi:10.1001/jama.2020.6019. PMID 32282022.
  59. Carod-Artal FJ (May 2020). "Neurological complications of coronavirus and COVID-19". Revista de Neurologia. 70 (9): 311–322. doi:10.33588/rn.7009.2020179. PMID 32329044.
  60. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P (May 2020). "Hyperinflammatory shock in children during COVID-19 pandemic". The Lancet. doi:10.1016/s0140-6736(20)31094-1. PMC 7204765. PMID 32386565.
  61. "Getting a handle on asymptomatic SARS-CoV-2 infection | Scripps Research". www.scripps.edu (in English). Retrieved 16 May 2020.
  62. "New coronavirus stable for hours on surfaces". National Institutes of Health. 17 March 2020. Archived from the original on 23 March 2020. Retrieved 30 April 2020.
  63. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. (April 2020). "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1". The New England Journal of Medicine. 382 (16): 1564–1567. doi:10.1056/NEJMc2004973. PMC 7121658. PMID 32182409.
  64. "Household cleaners and disinfectants can cause health problems when not used properly". Centers for Disease Control and Prevention (CDC). 24 April 2020. Retrieved 6 May 2020.
  65. 65.0 65.1 To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JM, et al. (February 2020). "Consistent detection of 2019 novel coronavirus in saliva". Clinical Infectious Diseases. Oxford University Press. doi:10.1093/cid/ciaa149. PMC 7108139. PMID 32047895.
  66. "COVID-19 and Our Communities -ACON – We are a New South Wales based health promotion organisation specialising in HIV prevention, HIV support and lesbian, gay, bisexual, transgender and intersex (LGBTI) health". Acon.org.au. Retrieved 29 April 2020.
  67. "Sex and Coronavirus Disease 2019 (COVID-19)" (PDF). nyc.gov. 27 March 2020. Retrieved 29 April 2020.
  68. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J (2012). "Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review". PLOS ONE. 7 (4): e35797. Bibcode:2012PLoSO...735797T. doi:10.1371/journal.pone.0035797. PMC 3338532. PMID 22563403.
  69. "Novel Coronavirus - Information for Clinicians" (PDF). Australian Government Dept of Health.
  70. "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China—fourth update" (PDF). European Centre for Disease Prevention and Control. 14 February 2020. Retrieved 8 March 2020.
  71. 71.0 71.1 Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (April 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615.
  72. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (February 2020). "A Novel Coronavirus from Patients with Pneumonia in China, 2019". The New England Journal of Medicine. 382 (8): 727–733. doi:10.1056/NEJMoa2001017. PMC 7092803. PMID 31978945.
  73. Cyranoski D (March 2020). "Mystery deepens over animal source of coronavirus". Nature. 579 (7797): 18–19. Bibcode:2020Natur.579...18C. doi:10.1038/d41586-020-00548-w. PMID 32127703.
  74. Letko M, Marzi A, Munster V (April 2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology. 5 (4): 562–569. doi:10.1038/s41564-020-0688-y. PMC 7095430. PMID 32094589.
  75. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (April 2020). "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target". Intensive Care Medicine. 46 (4): 586–590. doi:10.1007/s00134-020-05985-9. PMC 7079879. PMID 32125455.
  76. 76.0 76.1 Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. (February 2020). "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa". International Journal of Oral Science. 12 (1): 8. doi:10.1038/s41368-020-0074-x. PMC 7039956. PMID 32094336.
  77. Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics". Drug Development Research. doi:10.1002/ddr.21656. PMID 32129518.
  78. Li YC, Bai WZ, Hashikawa T (February 2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". Journal of Medical Virology. 92 (6): 552–555. doi:10.1002/jmv.25728. PMID 32104915.
  79. Baig AM, Khaleeq A, Ali U, Syeda H (April 2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. PMC 7094171. PMID 32167747.
  80. Gu J, Han B, Wang J (May 2020). "COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission". Gastroenterology. 158 (6): 1518–1519. doi:10.1053/j.gastro.2020.02.054. PMC 7130192. PMID 32142785.
  81. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (June 2004). "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis". The Journal of Pathology. 203 (2): 631–7. doi:10.1002/path.1570. PMC 7167720. PMID 15141377.
  82. 82.0 82.1 82.2 Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904.
  83. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. (February 2020). "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China". JAMA. 323 (11): 1061–1069. doi:10.1001/jama.2020.1585. PMC 7042881. PMID 32031570.
  84. Turner AJ, Hiscox JA, Hooper NM (June 2004). "ACE2: from vasopeptidase to SARS virus receptor". Trends in Pharmacological Sciences. 25 (6): 291–4. doi:10.1016/j.tips.2004.04.001. PMC 7119032. PMID 15165741.
  85. 85.0 85.1 Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. (April 2020). "Incidence of thrombotic complications in critically ill ICU patients with COVID-19". Thrombosis Research. doi:10.1016/j.thromres.2020.04.013. PMC 7146714. PMID 32291094.
  86. Cui S, Chen S, Li X, Liu S, Wang F (April 2020). "Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia". Journal of Thrombosis and Haemostasis. doi:10.1111/jth.14830. PMID 32271988.
  87. 87.0 87.1 Wadman M (April 2020). "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science. doi:10.1126/science.abc3208.
  88. Coronavirus: Kidney Damage Caused by COVID-19, Johns Hopkins Medicine, C. John Sperati, updated May 14, 2020.
  89. 89.0 89.1 Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S (May 2020). "COVID-19 Autopsies, Oklahoma, USA". American Journal of Clinical Pathology. 153 (6): 725–733. doi:10.1093/ajcp/aqaa062. PMC 7184436. PMID 32275742.
  90. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality". International Journal of Antimicrobial Agents: 105954. doi:10.1016/j.ijantimicag.2020.105954. PMC 7118634. PMID 32234467.
  91. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. (2020). "Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus". bioRxiv Pre-print: 2020.02.12.945576. doi:10.1101/2020.02.12.945576.
  92. "CDC Tests for 2019-nCoV". Centers for Disease Control and Prevention (CDC). 5 February 2020. Archived from the original on 14 February 2020. Retrieved 12 February 2020.
  93. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Archived from the original on 17 March 2020. Retrieved 13 March 2020.
  94. "2019 Novel Coronavirus (2019-nCoV) Situation Summary". Centers for Disease Control and Prevention. 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
  95. "Real-Time RT-PCR Panel for Detection 2019-nCoV". Centers for Disease Control and Prevention. 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
  96. "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
  97. Brueck H (30 January 2020). "There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus". Business Insider. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
  98. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". Archived from the original on 21 February 2020. Retrieved 26 February 2020.
  99. Cohen J, Normile D (January 2020). "New SARS-like virus in China triggers alarm" (PDF). Science. 367 (6475): 234–235. Bibcode:2020Sci...367..234C. doi:10.1126/science.367.6475.234. PMID 31949058. Archived (PDF) from the original on 11 February 2020. Retrieved 11 February 2020.
  100. "Severe acute respiratory syndrome coronavirus 2 data hub". NCBI. Archived from the original on 21 March 2020. Retrieved 4 March 2020.
  101. Petherick A (April 2020). "Developing antibody tests for SARS-CoV-2". Lancet. 395 (10230): 1101–1102. doi:10.1016/s0140-6736(20)30788-1. PMID 32247384.
  102. Vogel G (March 2020). "New blood tests for antibodies could show true scale of coronavirus pandemic". Science. doi:10.1126/science.abb8028.
  103. Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. (February 2020). "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review". Journal of Clinical Medicine. 9 (3): 623. doi:10.3390/jcm9030623. PMC 7141113. PMID 32110875.
  104. AFP News Agency (11 April 2020). "How false negatives are complicating COVID-19 testing". Al Jazeera website Retrieved 12 April 2020.
  105. "Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic" (Press release). FDA. 21 March 2020. Archived from the original on 21 March 2020. Retrieved 22 March 2020.
  106. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (February 2020). "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)". Military Medical Research. 7 (1): 4. doi:10.1186/s40779-020-0233-6. PMC 7003341. PMID 32029004.
  107. Lee EY, Ng MY, Khong PL (April 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases. 20 (4): 384–385. doi:10.1016/S1473-3099(20)30134-1. PMC 7128449. PMID 32105641. Archived from the original on 8 March 2020. Retrieved 13 March 2020.
  108. "ICD-10 Version:2019". World Health Organization. 2019. Archived from the original on 31 March 2020. Retrieved 31 March 2020. U07.2—COVID-19, virus not identified—COVID-19 NOS—Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestations
  109. Hanley B, Lucas SB, Youd E, Swift B, Osborn M (May 2020). "Autopsy in suspected COVID-19 cases". Journal of Clinical Pathology. 73 (5): 239–242. doi:10.1136/jclinpath-2020-206522. PMID 32198191.
  110. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. (March 2020). "[A pathological report of three COVID-19 cases by minimally invasive autopsies]". Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology (in Chinese). 49: E009. doi:10.3760/cma.j.cn112151-20200312-00193. PMID 32172546.CS1 maint: unrecognized language (link)
  111. Giani M, Seminati D, Lucchini A, Foti G, Pagni F (May 2020). "Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe". Journal of Thoracic Oncology. 15 (5): e65–e66. doi:10.1016/j.jtho.2020.03.008. PMC 7118681. PMID 32194247.
  112. Lillicrap D (April 2020). "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia". Journal of Thrombosis and Haemostasis. 18 (4): 786–787. doi:10.1111/jth.14781. PMC 7166410. PMID 32212240.
  113. Mitra A, Dwyre DM, Schivo M, Thompson GR, Cohen SH, Ku N, Graff JP (March 2020). "Leukoerythroblastic reaction in a patient with COVID-19 infection". American Journal of Hematology. doi:10.1002/ajh.25793. PMID 32212392.
  114. Wiles S (9 March 2020). "The three phases of Covid-19—and how we can make it manageable". The Spinoff. Archived from the original on 27 March 2020. Retrieved 9 March 2020.
  115. 115.0 115.1 115.2 115.3 Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi:10.1016/S0140-6736(20)30567-5. PMC 7158572. PMID 32164834. A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
  116. Barclay E (10 March 2020). "How canceled events and self-quarantines save lives, in one chart". Vox. Archived from the original on 12 March 2020. Retrieved 12 March 2020.
  117. Barclay E, Scott D, Animashaun A (7 April 2020). "The US doesn't just need to flatten the curve. It needs to "raise the line."". Vox. Archived from the original on 7 April 2020.
  118. 118.0 118.1 Wiles S (14 March 2020). "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". The Spinoff. Archived from the original on 26 March 2020. Retrieved 13 March 2020.
  119. 119.0 119.1 119.2 119.3 [[Centers for Disease Control and Prevention]|Centers for Disease Control and Prevention]] (3 February 2020). "Coronavirus Disease 2019 (COVID-19): Prevention & Treatment". Archived from the original on 15 December 2019. Retrieved 10 February 2020.
  120. World Health Organization. "Advice for Public". Archived from the original on 26 January 2020. Retrieved 10 February 2020.
  121. "My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub". NPR.org. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  122. 122.0 122.1 "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 17 April 2020.
  123. 123.0 123.1 123.2 123.3 "COVID-19 Treatment Guidelines". www.nih.gov. National Institutes of Health. Retrieved 21 April 2020.
  124. Maragakis LL. "Coronavirus, Social Distancing and Self Quarantine". www.hopkinsmedicine.org. Johns Hopkins University. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  125. Parker-Pope T (19 March 2020). "Deciding How Much Distance You Should Keep". The New York Times. ISSN 0362-4331. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  126. 126.0 126.1 126.2 126.3 126.4 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. doi:10.1001/jama.2020.6019. PMID 32282022.
  127. Systrom K, Krieger M, O'Rourke R, Stein R, Dellaert F, Lerer A (11 April 2020). "Rt Covid-19". rt.live. Retrieved 19 April 2020. Based on Bettencourt LM, Ribeiro RM (May 2008). "Real time bayesian estimation of the epidemic potential of emerging infectious diseases". PloS One. 3 (5): e2185. Bibcode:2008PLoSO...3.2185B. doi:10.1371/journal.pone.0002185. PMC 2366072. PMID 18478118.
  128. Grenfell R, Drew T (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". Science Alert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
  129. "When and how to use masks". World Health Organization (WHO). Archived from the original on 7 March 2020. Retrieved 8 March 2020.
  130. Staff (8 April 2020). "Using face masks in the community—Technical Report" (PDF). ECDC.
  131. "For different groups of people: how to choose masks". NHC.gov.cn. National Health Commission of the People's Republic of China. 7 February 2020. Retrieved 22 March 2020. Disposable medical masks: Recommended for: · People in crowded places · Indoor working environment with a relatively dense population · People going to medical institutions · Children in kindergarten and students at school gathering to study and do other activities[permanent dead link]
  132. "Prevention of Coronavirus Disease 2019 (COVID-19)" (PDF). Centre for Health Protection. Archived (PDF) from the original on 21 March 2020. Retrieved 22 March 2020. Wear a surgical mask when taking public transport or staying in crowded places.
  133. Staff (11 April 2020). "Spain officially recommends face mask use". Gazette Life. Retrieved 20 April 2020.
  134. Giuffrida A, Beaumont P (5 April 2020). "Lombardy insists on face masks outside homes to stop Covid-19". The Guardian. ISSN 0261-3077. Retrieved 20 April 2020.
  135. "Russian sanitary watchdog chief supports regions binding people to wear face masks". Tass. 1 May 2020. Retrieved 3 May 2020.
  136. "Coronavirus Disease 2019 (COVID-19)—Prevention & Treatment". Centers for Disease Control and Prevention (CDC). U.S. Department of Health & Human Services. 10 March 2020. Archived from the original on 11 March 2020. Retrieved 11 March 2020.
  137. "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization. 19 March 2009. Retrieved 19 March 2020.
  138. 138.0 138.1 Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi:10.1186/s12916-020-01533-w. PMC 7047369. PMID 32106852.
  139. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (May 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal. 133 (9): 1025–1031. doi:10.1097/CM9.0000000000000744. PMC 7147277. PMID 32044814.
  140. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. Elsevier BV. 395 (10228): e52. doi:10.1016/s0140-6736(20)30558-4. PMID 32171074.
  141. Henry BM (April 2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet. Respiratory Medicine. Elsevier BV. 8 (4): e24. doi:10.1016/s2213-2600(20)30119-3. PMC 7118650. PMID 32178774.
  142. Wang L, Wang Y, Ye D, Liu Q (March 2020). "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence". International Journal of Antimicrobial Agents: 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC 7156162. PMID 32201353. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
  143. Wang Y, Wang Y, Chen Y, Qin Q (March 2020). "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures". Journal of Medical Virology. n/a (n/a): 568–576. doi:10.1002/jmv.25748. PMID 32134116.
  144. Cheng ZJ, Shan J (April 2020). "2019 Novel coronavirus: where we are and what we know". Infection. 48 (2): 155–163. doi:10.1007/s15010-020-01401-y. PMC 7095345. PMID 32072569.
  145. "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 13 February 2020.
  146. Farkas J (March 2020). COVID-19—The Internet Book of Critical Care (digital) (Reference manual). USA: EMCrit. Archived from the original on 11 March 2020. Retrieved 13 March 2020.
  147. "COVID19—Resources for Health Care Professionals". Penn Libraries. 11 March 2020. Archived from the original on 14 March 2020. Retrieved 13 March 2020.
  148. "Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID‐19 Patients" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020. This article incorporates text from this source, which is in the public domain.
  149. Day M (March 2020). "Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists". BMJ. 368: m1086. doi:10.1136/bmj.m1086. PMID 32184201. Archived from the original on 19 March 2020. Retrieved 18 March 2020.
  150. "Self-isolation advice—Coronavirus (COVID-19)". National Health Service (United Kingdom). 28 February 2020. Archived from the original on 28 March 2020. Retrieved 27 March 2020.
  151. Godoy M (18 March 2020). "Concerned About Taking Ibuprofen For Coronavirus Symptoms? Here's What Experts Say". NPR. Retrieved 8 April 2020.
  152. AFP (19 March 2020). "Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms". ScienceAlert. Archived from the original on 18 March 2020. Retrieved 19 March 2020.
  153. Research, Center for Drug Evaluation and (19 March 2020). "FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19". Drug Safety and Availability. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
  154. "Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician". Archived from the original on 21 March 2020. Retrieved 21 March 2020.
  155. "Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician". American Heart Association (Press release). 17 March 2020. Archived from the original on 24 March 2020. Retrieved 25 March 2020.
  156. de Simone G. "Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers". Council on Hypertension of the European Society of Cardiology. Archived from the original on 24 March 2020. Retrieved 24 March 2020.
  157. "New Evidence Concerning Safety of ACE Inhibitors, ARBs in COVID-19". Pharmacy Times. Retrieved 2 May 2020.
  158. Vetter P, Eckerle I, Kaiser L (February 2020). "Covid-19: a puzzle with many missing pieces". BMJ. 368: m627. doi:10.1136/bmj.m627. PMID 32075791.
  159. "Novel Coronavirus—COVID-19: What Emergency Clinicians Need to Know". www.ebmedicine.net. Archived from the original on 14 March 2020. Retrieved 9 March 2020.
  160. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (May 2020). "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy". Journal of Thrombosis and Haemostasis. 18 (5): 1094–1099. doi:10.1111/jth.14817. PMID 32220112.
  161. "Sequence for Putting On Personal Protective Equipment (PPE)" (PDF). Centers for Disease Control and Prevention (CDC). Archived (PDF) from the original on 5 March 2020. Retrieved 8 March 2020.
  162. Cheung JC, Ho LT, Cheng JV, Cham EY, Lam KN (April 2020). "Staff safety during emergency airway management for COVID-19 in Hong Kong". The Lancet. Respiratory Medicine. 8 (4): e19. doi:10.1016/s2213-2600(20)30084-9. PMC 7128208. PMID 32105633.
  163. "What healthcare personnel should know about caring for patients with confirmed or possible coronavirus disease 2" (PDF). Centers for Disease Control and Prevention (CDC). 12 March 2020. Retrieved 31 March 2020.
  164. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 11 March 2020.
  165. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 8 March 2020.
  166. "Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 25 March 2020.
  167. "Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions". Food and Drug Administration.
  168. "Strategies for Optimizing the Supply of Facemasks". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 23 March 2020. Retrieved 23 March 2020.
  169. 169.0 169.1 169.2 Murthy S, Gomersall CD, Fowler RA (March 2020). "Care for Critically Ill Patients With COVID-19". JAMA. 323 (15): 1499. doi:10.1001/jama.2020.3633. PMID 32159735. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  170. World Health Organization (28 January 2020). "Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected" (PDF). Archived (PDF) from the original on 26 February 2020. Retrieved 18 March 2020.
  171. Wang K, Zhao W, Li J, Shu W, Duan J (March 2020). "The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China". Annals of Intensive Care. 10 (1): 37. doi:10.1186/s13613-020-00653-z. PMC 7104710. PMID 32232685.
  172. McEnery T, Gough C, Costello RW (April 2020). "COVID-19: Respiratory support outside the intensive care unit". The Lancet. Respiratory Medicine. doi:10.1016/S2213-2600(20)30176-4. PMC 7146718. PMID 32278367.
  173. 173.0 173.1 Scott, Dylan (16 March 2020). "Coronavirus is exposing all of the weaknesses in the US health system High health care costs and low medical capacity made the US uniquely vulnerable to the coronavirus". Vox. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  174. 174.0 174.1 Matthay MA, Aldrich JM, Gotts JE (May 2020). "Treatment for severe acute respiratory distress syndrome from COVID-19". The Lancet. Respiratory Medicine. 8 (5): 433–434. doi:10.1016/S2213-2600(20)30127-2. PMC 7118607. PMID 32203709.
  175. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, et al. (March 2010). "Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis". JAMA. 303 (9): 865–73. doi:10.1001/jama.2010.218. PMID 20197533.
  176. Diaz R, Heller D (2020). Barotrauma And Mechanical Ventilation. StatPearls. StatPearls Publishing. PMID 31424810.
  177. "Chinese doctors using plasma therapy on coronavirus, WHO says 'very valid' approach". Reuters. 17 February 2020. Archived from the original on 4 March 2020. Retrieved 19 March 2020.
  178. Steenhuysen J, Kelland K (24 January 2020). "With Wuhan virus genetic code in hand, scientists begin work on a vaccine". Reuters. Archived from the original on 25 January 2020. Retrieved 25 January 2020.
  179. Duddu P (19 February 2020). "Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19". clinicaltrialsarena.com. Archived from the original on 19 February 2020.
  180. Lu H (March 2020). "Drug treatment options for the 2019-new coronavirus (2019-nCoV)". Bioscience Trends. 14 (1): 69–71. doi:10.5582/bst.2020.01020. PMID 31996494.
  181. 181.0 181.1 181.2 181.3 Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–150. doi:10.1038/d41573-020-00016-0. PMID 32127666.
  182. Nebehay S, Kelland K, Liu R (5 February 2020). "WHO: 'no known effective' treatments for new coronavirus". Thomson Reuters. Archived from the original on 5 February 2020. Retrieved 5 February 2020.
  183. "Blood plasma taken from covid-19 survivors might help patients fight off the disease". MIT Technology Review.
  184. "Trials of Plasma From Recovered Covid-19 Patients Have Begun". Wired.
  185. "FDA now allows treatment of life-threatening COVID-19 cases using blood from patients who have recovered". TechCrunch. Retrieved 9 April 2020.
  186. "China launches coronavirus 'close contact' app". BBC News. 11 February 2020. Archived from the original on 28 February 2020. Retrieved 7 March 2020.
  187. Chen A. "China's coronavirus app could have unintended consequences". MIT Technology Review. Retrieved 7 March 2020.
  188. "Gov in the Time of Corona". GovInsider. 19 March 2020. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  189. Manancourt V (10 March 2020). "Coronavirus tests Europe's resolve on privacy". POLITICO. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  190. Tidy J (17 March 2020). "Coronavirus: Israel enables emergency spy powers". BBC News. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  191. Bünte O (18 March 2020). "Corona-Krise: Deutsche Telekom liefert anonymisierte Handydaten an RKI" [Corona crisis: Deutsche Telekom delivers anonymized cell phone data to RKI]. Heise Online (in German). Archived from the original on 24 March 2020. Retrieved 25 March 2020.CS1 maint: unrecognized language (link)
  192. "Moscow deploys facial recognition technology for coronavirus quarantine". Reuters. 21 February 2020. Archived from the original on 22 February 2020. Retrieved 20 March 2020.
  193. "Italians scolded for flouting lockdown as death toll nears 3,000". Pittsburgh Post-Gazette. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  194. "Kreative Lösungen gesucht". Startseite (in Deutsch). Archived from the original on 24 March 2020. Retrieved 23 March 2020.
  195. Dannewitz J (23 March 2020). "Hackathon Germany: #WirvsVirus". Datenschutzbeauftragter (in Deutsch).
  196. Staff (8 April 2020). "Lockdown is working, suggests latest data from symptom tracker app". Kings College London News Centre. Retrieved 20 April 2020.
  197. Lydall, Ross (4 May 2020). "Three million download app to track coronavirus symptoms". Evening Standard. Retrieved 8 May 2020.
  198. Whyte A (21 March 2020). "President makes global call to combat coronavirus via hackathon". ERR. Archived from the original on 24 March 2020. Retrieved 23 March 2020.
  199. Xiang YT, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, Ng CH (March 2020). "Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed". The Lancet. Psychiatry. 7 (3): 228–229. doi:10.1016/S2215-0366(20)30046-8. PMC 7128153. PMID 32032543.
  200. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, et al. (March 2020). "The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus". The Lancet. Psychiatry. 7 (3): e14. doi:10.1016/S2215-0366(20)30047-X. PMC 7129673. PMID 32035030.
  201. Coronavirus: 'Profound' mental health impact prompts calls for urgent research, BBC, Philippa Roxby, April 16, 2020.
  202. Multidisciplinary research priorities for the COVID‑19 pandemic: a call for action for mental health science, The Lancet, Emily Holmes, Rory O'Connor, Hugh Perry, et al., April 15, 2020, page 1: "A fragmented research response, characterised by small-scale and localised initiatives, will not yield the clear insights necessary to guide policymakers or the public."
  203. Roser M, Ritchie H, Ortiz-Ospina E (4 March 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Archived from the original on 19 March 2020. Retrieved 12 March 2020.
  204. 204.0 204.1 204.2 204.3 Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 February 2020). "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China, 2020". China CDC Weekly. Chinese Center for Disease Control and Prevention. 2 (8): 113–122. Archived from the original on 19 February 2020. Retrieved 18 March 2020.
  205. 205.0 205.1 26 additional cases have been confirmed (Report). Korea Centers for Disease Control and Prevention. 13 May 2020. Retrieved 13 May 2020.
  206. 206.0 206.1 Actualización nº 104. Enfermedad por el coronavirus (COVID-19) (PDF) (Report) (in Spanish). Ministerio de Sanidad, Consumo y Bienestar Social. 13 May 2020. Retrieved 13 May 2020.CS1 maint: unrecognized language (link)
  207. 207.0 207.1 Epidemia COVID-19. Aggiornamento nazionale 7 maggio 2020 (PDF) (Report) (in Italian). Rome: Istituto Superiore di Sanità. 8 May 2020. Retrieved 10 May 2020.CS1 maint: unrecognized language (link)
  208. Roser M, Ritchie H, Ortiz-Ospina E (6 April 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Retrieved 6 April 2020.
  209. 209.0 209.1 Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. (April 2020). "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review". JAMA Pediatrics. doi:10.1001/jamapediatrics.2020.1467. PMID 32320004.
  210. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. (April 2020). "SARS-CoV-2 Infection in Children". The New England Journal of Medicine. Massachusetts Medical Society. 382 (17): 1663–1665. doi:10.1056/nejmc2005073. PMC 7121177. PMID 32187458.
  211. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (March 2020). "Epidemiology of COVID-19 Among Children in China" (PDF). Pediatrics: e20200702. doi:10.1542/peds.2020-0702. PMID 32179660. Archived (PDF) from the original on 17 March 2020. Retrieved 16 March 2020.
  212. Fang L, Karakiulakis G, Roth M (April 2020). "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?". The Lancet. Respiratory Medicine. 8 (4): e21. doi:10.1016/S0140-6736(20)30311-1. PMC 7118626. PMID 32171062.
  213. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 2 March 2020. Retrieved 2 March 2020.
  214. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. (March 2020). "Dysregulation of immune response in patients with COVID-19 in Wuhan, China". Clinical Infectious Diseases. doi:10.1093/cid/ciaa248. PMC 7108125. PMID 32161940.
  215. "WHO Director-General's statement on the advice of the IHR Emergency Committee on Novel Coronavirus". World Health Organization (WHO).
  216. 216.0 216.1 Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, et al. (3 April 2020). Characteristics of COVID-19 patients dying in Italy Report based on available data on April 2th, 2020 (PDF) (Report). Istituto Superiore di Sanità. Retrieved 3 April 2020.
  217. Wang W, Tang J, Wei F (April 2020). "Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China". Journal of Medical Virology. 92 (4): 441–447. doi:10.1002/jmv.25689. PMC 7167192. PMID 31994742.
  218. "Coronavirus Age, Sex, Demographics (COVID-19)". www.worldometers.info. Archived from the original on 27 February 2020. Retrieved 26 February 2020.
  219. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. (April 2020). "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (15): 458–464. doi:10.15585/mmwr.mm6915e3. PMID 32298251.
  220. Ji Y, Ma Z, Peppelenbosch MP, Pan Q (April 2020). "Potential association between COVID-19 mortality and health-care resource availability". The Lancet. Global Health. 8 (4): e480. doi:10.1016/S2214-109X(20)30068-1. PMC 7128131. PMID 32109372.
  221. Li XQ, Cai WF, Huang LF, Chen C, Liu YF, Zhang ZB, et al. (March 2020). "[Comparison of epidemic characteristics between SARS in2003 and COVID-19 in 2020 in Guangzhou]". Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi (in Chinese). 41 (5): 634–637. doi:10.3760/cma.j.cn112338-20200228-00209. PMID 32159317.CS1 maint: unrecognized language (link)
  222. Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. (February 2020). "Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases". Journal of Clinical Medicine. 9 (2): 523. doi:10.3390/jcm9020523. PMC 7074479. PMID 32075152.
  223. Chughtai A, Malik A (March 2020). "Is Coronavirus disease (COVID-19) case fatality ratio underestimated?". Global Biosecurity. 1 (3). doi:10.31646/gbio.56 (inactive 26 April 2020).
  224. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (March 2020). "Real estimates of mortality following COVID-19 infection". The Lancet. Infectious Diseases. doi:10.1016/S1473-3099(20)30195-X. PMC 7118515. PMID 32171390.
  225. Vardavas CI, Nikitara K (20 March 2020). "COVID-19 and smoking: A systematic review of the evidence". Tobacco Induced Diseases. 18 (March): 20. doi:10.18332/tid/119324. PMC 7083240. PMID 32206052.
  226. Cheung E (13 March 2020). "Some recovered Covid-19 patients may have lung damage, doctors say". South China Morning Post. Archived from the original on 15 March 2020. Retrieved 15 March 2020.
  227. Servick K (8 April 2020). "For survivors of severe COVID-19, beating the virus is just the beginning". Science. doi:10.1126/science.abc1486. ISSN 0036-8075.
  228. "Sala de Situación COVID-19 Nuevo Coronavirus 2019 Novedades al 07/05 - 18 hs- SE 19" (PDF) (in Spanish). 7 May 2020.CS1 maint: unrecognized language (link)
  229. https://www.health.gov.au/resources/covid-19-deaths-by-age-group-and-sex https://www.health.gov.au/resources/covid-19-cases-by-age-group-and-sex
  230. "Coronavirus Disease 2019 (COVID-19) DAILY EPIDEMIOLOGY UPDATE Updated: 12 May, 2020, 11:00 AM ET" (PDF). Public Health Agency of Canada. 12 May 2020. Retrieved 13 May 2020.
  231. https://cdn.digital.gob.cl/public_files/Campa%C3%B1as/Corona-Virus/Reportes/11.05.2020_Reporte_Covid19.pdf https://www.minsal.cl/16-informe-epidemiologico-covid-19/
  232. COVID-19 i Danmark: Epidemiologisk overvågningsrapport den 13. maj 2020 (Report) (in Danish). Statens Serum Institut. 13 May 2020. Retrieved 13 May 2020.CS1 maint: unrecognized language (link)
  233. "Experience". experience.arcgis.com.
  234. "Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute 09/05/2020 - UPDATED STATUS FOR GERMANY" (PDF). Robert Koch Institute.
  235. "קורונה - משרד הבריאות". Ministry of Health (Israel). 3 May 2020. Retrieved 5 May 2020.
  236. https://toyokeizai.net/sp/visual/tko/covid19/en.html
  237. Epidemiologische situatie COVID-19 in Nederland 8 mei 2020 (Report) (in Dutch). Bilthoven: Rijksinstituut voor Volksgezondheid en Milie. 8 May 2020. Retrieved 8 May 2020.CS1 maint: unrecognized language (link)
  238. "COVID-19 Dagsrapport" (PDF). Folkehelseinstituttet.
  239. "NOVO CORONAVÍRUS COVID-19 RELATÓRIO DE SITUAÇÃO" (PDF) (in português). 13 May 2020. Retrieved 13 May 2020.
  240. "FOHM Covid-19". Public Health Agency of Sweden. Retrieved 13 May 2020.
  241. "Todesfälle in der Schweiz nach Altersgruppen". datawrapper.dwcdn.net. 13 May 2020. Retrieved 13 May 2020.
  242. "COVID-19 confirmed cases and deaths by age group | Connecticut Data". data.ct.gov. 12 May 2020. Retrieved 13 May 2020.
  243. "Tableau Public". public.tableau.com.
  244. The time allocated for running scripts has expired.
  245. https://coronavirus.maryland.gov Probable but not lab-confirmed deaths not included
  246. The time allocated for running scripts has expired.
  247. The time allocated for running scripts has expired.
  248. https://www.dhhs.nh.gov/dphs/cdcs/covid19/covid-weekly-report-05042020.pdf
  249. https://govstatus.egov.com/OR-OHA-COVID-19
  250. https://dshs.texas.gov/coronavirus/additionaldata/
  251. https://public.tableau.com/views/VirginiaCOVID-19Dashboard/Demographics
  252. The time allocated for running scripts has expired.
  253. The time allocated for running scripts has expired.
  254. The time allocated for running scripts has expired.
  255. The time allocated for running scripts has expired.
  256. The time allocated for running scripts has expired.
  257. The time allocated for running scripts has expired.
  258. The time allocated for running scripts has expired.
  259. The time allocated for running scripts has expired.
  260. 260.0 260.1 The time allocated for running scripts has expired.
  261. The time allocated for running scripts has expired.
  262. The time allocated for running scripts has expired.
  263. The time allocated for running scripts has expired.
  264. The time allocated for running scripts has expired.
  265. The time allocated for running scripts has expired.
  266. The time allocated for running scripts has expired.
  267. The time allocated for running scripts has expired.
  268. The time allocated for running scripts has expired.
  269. The time allocated for running scripts has expired.
  270. The time allocated for running scripts has expired.
  271. The time allocated for running scripts has expired.
  272. The time allocated for running scripts has expired.
  273. The time allocated for running scripts has expired.
  274. The time allocated for running scripts has expired.
  275. The time allocated for running scripts has expired.
  276. 276.0 276.1 The time allocated for running scripts has expired.
  277. The time allocated for running scripts has expired.
  278. The time allocated for running scripts has expired.
  279. The time allocated for running scripts has expired.
  280. The time allocated for running scripts has expired.
  281. The time allocated for running scripts has expired.
  282. 282.0 282.1 The time allocated for running scripts has expired.
  283. The time allocated for running scripts has expired.
  284. The time allocated for running scripts has expired.
  285. The time allocated for running scripts has expired.
  286. The time allocated for running scripts has expired.
  287. The time allocated for running scripts has expired.
  288. The time allocated for running scripts has expired.
  289. The time allocated for running scripts has expired.
  290. The time allocated for running scripts has expired.
  291. The time allocated for running scripts has expired.
  292. The time allocated for running scripts has expired.
  293. The time allocated for running scripts has expired.
  294. 294.0 294.1 294.2 The time allocated for running scripts has expired.
  295. The time allocated for running scripts has expired.
  296. 296.0 296.1 296.2 296.3 The time allocated for running scripts has expired.
  297. The time allocated for running scripts has expired.
  298. 298.0 298.1 The time allocated for running scripts has expired.
  299. The time allocated for running scripts has expired.
  300. The time allocated for running scripts has expired.
  301. 301.0 301.1 The time allocated for running scripts has expired.
  302. The time allocated for running scripts has expired.
  303. The time allocated for running scripts has expired.
  304. The time allocated for running scripts has expired.
  305. The time allocated for running scripts has expired.
  306. The time allocated for running scripts has expired.
  307. The time allocated for running scripts has expired.
  308. The time allocated for running scripts has expired.
  309. The time allocated for running scripts has expired.
  310. The time allocated for running scripts has expired.
  311. The time allocated for running scripts has expired.
  312. The time allocated for running scripts has expired.
  313. The time allocated for running scripts has expired.
  314. The time allocated for running scripts has expired.
  315. The time allocated for running scripts has expired.
  316. The time allocated for running scripts has expired.
  317. The time allocated for running scripts has expired.
  318. The time allocated for running scripts has expired.
  319. 319.0 319.1 The time allocated for running scripts has expired.
  320. The time allocated for running scripts has expired.
  321. The time allocated for running scripts has expired.
  322. The time allocated for running scripts has expired.
  323. The time allocated for running scripts has expired.
  324. The time allocated for running scripts has expired.
  325. The time allocated for running scripts has expired.
  326. 326.0 326.1 'Where are all our patients?': Covid phobia is keeping people with serious heart symptoms away from ERs, Stat News, Usha Lee McFarling, April 23, 2020.
  327. The time allocated for running scripts has expired.
  328. The time allocated for running scripts has expired.
  329. The time allocated for running scripts has expired.
  330. The time allocated for running scripts has expired.
  331. The time allocated for running scripts has expired.
  332. The time allocated for running scripts has expired.
  333. The time allocated for running scripts has expired.
  334. 334.0 334.1 The time allocated for running scripts has expired.
  335. The time allocated for running scripts has expired.
  336. The time allocated for running scripts has expired.
  337. The time allocated for running scripts has expired.
  338. The time allocated for running scripts has expired.
  339. The time allocated for running scripts has expired.
  340. 340.0 340.1 340.2 The time allocated for running scripts has expired.
  341. 341.0 341.1 341.2 341.3 The time allocated for running scripts has expired.
  342. The time allocated for running scripts has expired.
  343. The time allocated for running scripts has expired.
  344. The time allocated for running scripts has expired.
  345. The time allocated for running scripts has expired.
  346. The time allocated for running scripts has expired.
  347. The time allocated for running scripts has expired.
  348. 348.0 348.1 The time allocated for running scripts has expired.
  349. The time allocated for running scripts has expired.
  350. The time allocated for running scripts has expired.
  351. The time allocated for running scripts has expired.
  352. The time allocated for running scripts has expired.
  353. The time allocated for running scripts has expired.
  354. The time allocated for running scripts has expired.
  355. The time allocated for running scripts has expired.
  356. The time allocated for running scripts has expired.
  357. The time allocated for running scripts has expired.
  358. The time allocated for running scripts has expired.
  359. The time allocated for running scripts has expired.
  360. The time allocated for running scripts has expired.
  361. The time allocated for running scripts has expired.
  362. The time allocated for running scripts has expired.
  363. The time allocated for running scripts has expired.
  364. The time allocated for running scripts has expired.
  365. 365.0 365.1 365.2 365.3 The time allocated for running scripts has expired.
  366. The time allocated for running scripts has expired.

The time allocated for running scripts has expired.

External links

The time allocated for running scripts has expired.

Health agencies

Directories

Medical journals

The time allocated for running scripts has expired. The time allocated for running scripts has expired. Template:Viral diseases The time allocated for running scripts has expired. The time allocated for running scripts has expired.The time allocated for running scripts has expired.